More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $228.39 |
|
|||
| Open | $228.95 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $231.45 | ||||
| Day Low | $227.50 | ||||
| P/E | 48.09 | ||||
| EPS | $4.81 | ||||
| Volume | 8,518,208 | ||||
- Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
- Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
- Form 4 JOHNSON & JOHNSON For: Jun 11 Filed by: Wengel Kathryn E
- Leerink highlights drug demand rebound after Memorial Day
- Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Woods Eugene A.
- Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Pinto Daniel E
- Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: HEWSON MARILLYN A
Entities mentioned with JNJ
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
